Summit Therapeutics Inc (SMMT) said Monday it will collaborate with Pfizer (PFE) on a set of clinical trials to evaluate ivonescimab, its investigational drug, in combination with several Pfizer antibody drug conjugates to treat multiple solid tumors.
Financial terms were not disclosed.
Under the agreement, Summit will provide ivonescimab, while Pfizer will conduct the studies, which are planned to begin mid-2025 and will be overseen by both companies.
Each study will evaluate ivonescimab in combination with one of Pfizer's vedotin ADCs in distinct solid tumor settings to determine the safety profile and potential tumor-fighting ability of the combinations.
Summit shares were up 5% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。